Global Alpha-emitting Radiopharmaceutical Supply, Demand and Key Producers, 2026-2032
The global Alpha-emitting Radiopharmaceutical market size is expected to reach $ 334 million by 2032, rising at a market growth of 6.2% CAGR during the forecast period (2026-2032).
Alpha-emitting Radiopharmaceuticals are innovative therapeutic radiopharmaceuticals that use alpha-particle-emitting radionuclides as the core cytotoxic payload and deliver them precisely to tumor cells or disease microenvironments through small molecules, antibodies, peptides, ligands, or other targeting vectors. By releasing high-linear-energy-transfer radiation, they can induce double-strand DNA breaks and potent tumor cell killing. Compared with conventional external beam radiotherapy or certain beta-emitting radiopharmaceuticals, alpha particles have a shorter tissue range and higher energy density, enabling strong localized tumor destruction while potentially reducing unnecessary exposure to surrounding healthy tissues. This product category integrates nuclear medicine, targeted oncology, radiochemistry, isotope supply, companion diagnostics, and precision medicine, making it a frontier field in the evolution of radiopharmaceuticals from diagnosis to therapy and from single indications to broader oncology applications.The average gross profit margin of this product is 93%.
Alpha-emitting radiopharmaceuticals are entering a strategic window where nuclear medicine therapy and precision oncology are converging. As the clinical value of radioligand therapy continues to gain recognition globally, pharmaceutical companies, investors, and clinical institutions are showing growing interest in the model of ?diagnosis-guided precision killing.? The core appeal of alpha-emitting radiopharmaceuticals lies in their high energy, short tissue range, and strong ability to induce DNA damage, making them particularly attractive for minimal residual disease, heterogeneous solid tumors, bone metastases, and patient populations resistant to conventional therapies. The active investment of major pharmaceutical companies in radioconjugates, actinium-based platforms, and isotope supply chains is accelerating the field from early-stage research toward industrial competition. For CEOs, marketing leaders, and investors, alpha-emitting radiopharmaceuticals represent not only a new drug category but also a strategic entry point into targeted oncology, nuclear medicine infrastructure, and next-generation precision therapy platforms.
The challenges of alpha-emitting radiopharmaceuticals arise from the combined complexity of technology, regulation, manufacturing, and clinical translation. First, alpha-emitting radionuclides involve demanding requirements related to half-life, decay chains, daughter isotope migration, and radiochemical stability, meaning drug design must simultaneously achieve targeting efficiency, in vivo stability, and a safe therapeutic window. Second, radiopharmaceutical manufacturing requires specialized licenses, shielding facilities, hot cells, automated synthesis modules, radioactive waste management, and stringent GMP systems, creating significantly higher barriers than conventional innovative drugs. Third, clinical implementation depends on close collaboration among nuclear medicine, oncology, imaging, pharmacy, and radiation safety teams, while treatment-center readiness and patient workflow directly shape commercialization speed. At the same time, bone marrow suppression, renal toxicity, salivary gland injury, dosimetry assessment, and long-term safety remain core risks that companies must address seriously during clinical development and market access.
Downstream demand for alpha-emitting radiopharmaceuticals will evolve rapidly around difficult-to-treat cancers, precision patient stratification, and integrated diagnosis-treatment pathways. Oncology hospitals, nuclear medicine departments in general hospitals, prostate cancer centers, neuroendocrine tumor centers, bone metastasis treatment centers, and innovative drug clinical research institutions will become key early-use and market education settings. As PET/SPECT imaging, target testing, molecular profiling, and dosimetry management mature, downstream customers will evaluate these products not only by therapeutic efficacy but also by target selection, imaging confirmation, treatment accessibility, toxicity management, and multidisciplinary workflow efficiency. Future demand will no longer focus simply on whether a new radiopharmaceutical is available, but on whether a complete solution can be built from diagnosis, patient screening, dosing, monitoring, and retreatment. This will give stronger competitive advantages to companies with integrated pipelines, nuclear medicine channels, and treatment-center collaboration capabilities.
This report studies the global Alpha-emitting Radiopharmaceutical demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Alpha-emitting Radiopharmaceutical, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Alpha-emitting Radiopharmaceutical that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Alpha-emitting Radiopharmaceutical total market, 2021-2032, (USD Million)
Global Alpha-emitting Radiopharmaceutical total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Alpha-emitting Radiopharmaceutical total market, key domestic companies, and share, (USD Million)
Global Alpha-emitting Radiopharmaceutical revenue by player, revenue and market share 2021-2026, (USD Million)
Global Alpha-emitting Radiopharmaceutical total market by Type, CAGR, 2021-2032, (USD Million)
Global Alpha-emitting Radiopharmaceutical total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Alpha-emitting Radiopharmaceutical market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Eli Lilly, AstraZeneca, Fusion Pharmaceuticals, Telix Pharmaceuticals, RayzeBio, Orano Med, Actinium Pharmaceuticals, Alpha-9 Theranostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Alpha-emitting Radiopharmaceutical market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Alpha-emitting Radiopharmaceutical Market, By Region:
1. How big is the global Alpha-emitting Radiopharmaceutical market?
2. What is the demand of the global Alpha-emitting Radiopharmaceutical market?
3. What is the year over year growth of the global Alpha-emitting Radiopharmaceutical market?
4. What is the total value of the global Alpha-emitting Radiopharmaceutical market?
5. Who are the Major Players in the global Alpha-emitting Radiopharmaceutical market?
6. What are the growth factors driving the market demand?
Alpha-emitting Radiopharmaceuticals are innovative therapeutic radiopharmaceuticals that use alpha-particle-emitting radionuclides as the core cytotoxic payload and deliver them precisely to tumor cells or disease microenvironments through small molecules, antibodies, peptides, ligands, or other targeting vectors. By releasing high-linear-energy-transfer radiation, they can induce double-strand DNA breaks and potent tumor cell killing. Compared with conventional external beam radiotherapy or certain beta-emitting radiopharmaceuticals, alpha particles have a shorter tissue range and higher energy density, enabling strong localized tumor destruction while potentially reducing unnecessary exposure to surrounding healthy tissues. This product category integrates nuclear medicine, targeted oncology, radiochemistry, isotope supply, companion diagnostics, and precision medicine, making it a frontier field in the evolution of radiopharmaceuticals from diagnosis to therapy and from single indications to broader oncology applications.The average gross profit margin of this product is 93%.
Alpha-emitting radiopharmaceuticals are entering a strategic window where nuclear medicine therapy and precision oncology are converging. As the clinical value of radioligand therapy continues to gain recognition globally, pharmaceutical companies, investors, and clinical institutions are showing growing interest in the model of ?diagnosis-guided precision killing.? The core appeal of alpha-emitting radiopharmaceuticals lies in their high energy, short tissue range, and strong ability to induce DNA damage, making them particularly attractive for minimal residual disease, heterogeneous solid tumors, bone metastases, and patient populations resistant to conventional therapies. The active investment of major pharmaceutical companies in radioconjugates, actinium-based platforms, and isotope supply chains is accelerating the field from early-stage research toward industrial competition. For CEOs, marketing leaders, and investors, alpha-emitting radiopharmaceuticals represent not only a new drug category but also a strategic entry point into targeted oncology, nuclear medicine infrastructure, and next-generation precision therapy platforms.
The challenges of alpha-emitting radiopharmaceuticals arise from the combined complexity of technology, regulation, manufacturing, and clinical translation. First, alpha-emitting radionuclides involve demanding requirements related to half-life, decay chains, daughter isotope migration, and radiochemical stability, meaning drug design must simultaneously achieve targeting efficiency, in vivo stability, and a safe therapeutic window. Second, radiopharmaceutical manufacturing requires specialized licenses, shielding facilities, hot cells, automated synthesis modules, radioactive waste management, and stringent GMP systems, creating significantly higher barriers than conventional innovative drugs. Third, clinical implementation depends on close collaboration among nuclear medicine, oncology, imaging, pharmacy, and radiation safety teams, while treatment-center readiness and patient workflow directly shape commercialization speed. At the same time, bone marrow suppression, renal toxicity, salivary gland injury, dosimetry assessment, and long-term safety remain core risks that companies must address seriously during clinical development and market access.
Downstream demand for alpha-emitting radiopharmaceuticals will evolve rapidly around difficult-to-treat cancers, precision patient stratification, and integrated diagnosis-treatment pathways. Oncology hospitals, nuclear medicine departments in general hospitals, prostate cancer centers, neuroendocrine tumor centers, bone metastasis treatment centers, and innovative drug clinical research institutions will become key early-use and market education settings. As PET/SPECT imaging, target testing, molecular profiling, and dosimetry management mature, downstream customers will evaluate these products not only by therapeutic efficacy but also by target selection, imaging confirmation, treatment accessibility, toxicity management, and multidisciplinary workflow efficiency. Future demand will no longer focus simply on whether a new radiopharmaceutical is available, but on whether a complete solution can be built from diagnosis, patient screening, dosing, monitoring, and retreatment. This will give stronger competitive advantages to companies with integrated pipelines, nuclear medicine channels, and treatment-center collaboration capabilities.
This report studies the global Alpha-emitting Radiopharmaceutical demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Alpha-emitting Radiopharmaceutical, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Alpha-emitting Radiopharmaceutical that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Alpha-emitting Radiopharmaceutical total market, 2021-2032, (USD Million)
Global Alpha-emitting Radiopharmaceutical total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Alpha-emitting Radiopharmaceutical total market, key domestic companies, and share, (USD Million)
Global Alpha-emitting Radiopharmaceutical revenue by player, revenue and market share 2021-2026, (USD Million)
Global Alpha-emitting Radiopharmaceutical total market by Type, CAGR, 2021-2032, (USD Million)
Global Alpha-emitting Radiopharmaceutical total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Alpha-emitting Radiopharmaceutical market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Eli Lilly, AstraZeneca, Fusion Pharmaceuticals, Telix Pharmaceuticals, RayzeBio, Orano Med, Actinium Pharmaceuticals, Alpha-9 Theranostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Alpha-emitting Radiopharmaceutical market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Alpha-emitting Radiopharmaceutical Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Actinium-225 Radiopharmaceuticals
- Radium-223 Radiopharmaceuticals
- Lead-212 Radiopharmaceuticals
- Astatine-211 Radiopharmaceuticals
- Bismuth-213 Radiopharmaceuticals
- Other
- Prostate Cancer Targeted Agents
- Neuroendocrine Tumor Agents
- Hematologic Malignancy Agents
- Solid Tumor Agents
- Companion Diagnostic Enabled
- Other
- Ready-To-Use Injection
- Radiolabeling Kit
- Isotope Precursor
- Other
- Prostate Cancer
- Bone Metastases
- Neuroendocrine Tumors
- Hematologic Malignancies
- Other Solid Tumors
- Other
- Bayer
- Novartis
- Eli Lilly
- AstraZeneca
- Fusion Pharmaceuticals
- Telix Pharmaceuticals
- RayzeBio
- Orano Med
- Actinium Pharmaceuticals
- Alpha-9 Theranostics
- AdvanCell
- ITM Isotope Technologies Munich
- Curium
- China Isotope & Radiation
1. How big is the global Alpha-emitting Radiopharmaceutical market?
2. What is the demand of the global Alpha-emitting Radiopharmaceutical market?
3. What is the year over year growth of the global Alpha-emitting Radiopharmaceutical market?
4. What is the total value of the global Alpha-emitting Radiopharmaceutical market?
5. Who are the Major Players in the global Alpha-emitting Radiopharmaceutical market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Alpha-emitting Radiopharmaceutical Introduction
1.2 World Alpha-emitting Radiopharmaceutical Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Alpha-emitting Radiopharmaceutical Total Market by Region (by Headquarter Location)
1.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.3 China Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.4 Europe Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.5 Japan Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.6 South Korea Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.7 ASEAN Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.8 India Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Alpha-emitting Radiopharmaceutical Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.2 World Alpha-emitting Radiopharmaceutical Consumption Value by Region
2.2.1 World Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026)
2.2.2 World Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Region (2027-2032)
2.3 United States Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.4 China Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.5 Europe Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.6 Japan Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.7 South Korea Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.8 ASEAN Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.9 India Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
3 WORLD ALPHA-EMITTING RADIOPHARMACEUTICAL COMPANIES COMPETITIVE ANALYSIS
3.1 World Alpha-emitting Radiopharmaceutical Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Alpha-emitting Radiopharmaceutical Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Alpha-emitting Radiopharmaceutical in 2025
3.2.3 Global Concentration Ratios (CR8) for Alpha-emitting Radiopharmaceutical in 2025
3.3 Alpha-emitting Radiopharmaceutical Company Evaluation Quadrant
3.4 Alpha-emitting Radiopharmaceutical Market: Overall Company Footprint Analysis
3.4.1 Alpha-emitting Radiopharmaceutical Market: Region Footprint
3.4.2 Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
3.4.3 Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Alpha-emitting Radiopharmaceutical Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Alpha-emitting Radiopharmaceutical Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Alpha-emitting Radiopharmaceutical Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Alpha-emitting Radiopharmaceutical Consumption Value Comparison
4.2.1 United States VS China: Alpha-emitting Radiopharmaceutical Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Alpha-emitting Radiopharmaceutical Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Alpha-emitting Radiopharmaceutical Companies and Market Share, 2021-2026
4.3.1 United States Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026)
4.4 China Based Companies Alpha-emitting Radiopharmaceutical Revenue and Market Share, 2021-2026
4.4.1 China Based Alpha-emitting Radiopharmaceutical Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026)
4.5 Rest of World Based Alpha-emitting Radiopharmaceutical Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Alpha-emitting Radiopharmaceutical Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Actinium-225 Radiopharmaceuticals
5.2.2 Radium-223 Radiopharmaceuticals
5.2.3 Lead-212 Radiopharmaceuticals
5.2.4 Astatine-211 Radiopharmaceuticals
5.2.5 Bismuth-213 Radiopharmaceuticals
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
5.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Type (2027-2032)
5.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY INDICATION
6.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Indication: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Indication
6.2.1 Prostate Cancer Targeted Agents
6.2.2 Neuroendocrine Tumor Agents
6.2.3 Hematologic Malignancy Agents
6.2.4 Solid Tumor Agents
6.2.5 Companion Diagnostic Enabled
6.2.6 Other
6.3 Market Segment by Indication
6.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Indication (2021-2026)
6.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Indication (2027-2032)
6.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication (2027-2032)
7 MARKET ANALYSIS BY SUPPLY FORM
7.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Supply Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Supply Form
7.2.1 Ready-To-Use Injection
7.2.2 Radiolabeling Kit
7.2.3 Isotope Precursor
7.2.4 Other
7.3 Market Segment by Supply Form
7.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Supply Form (2021-2026)
7.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Supply Form (2027-2032)
7.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Prostate Cancer
8.2.2 Bone Metastases
8.2.3 Neuroendocrine Tumors
8.2.4 Hematologic Malignancies
8.2.5 Other Solid Tumors
8.2.6 Other
8.3 Market Segment by Application
8.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026)
8.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Application (2027-2032)
8.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Bayer
9.1.1 Bayer Details
9.1.2 Bayer Major Business
9.1.3 Bayer Alpha-emitting Radiopharmaceutical Product and Services
9.1.4 Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Bayer Recent Developments/Updates
9.1.6 Bayer Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Alpha-emitting Radiopharmaceutical Product and Services
9.2.4 Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Eli Lilly
9.3.1 Eli Lilly Details
9.3.2 Eli Lilly Major Business
9.3.3 Eli Lilly Alpha-emitting Radiopharmaceutical Product and Services
9.3.4 Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Eli Lilly Recent Developments/Updates
9.3.6 Eli Lilly Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca Alpha-emitting Radiopharmaceutical Product and Services
9.4.4 AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Fusion Pharmaceuticals
9.5.1 Fusion Pharmaceuticals Details
9.5.2 Fusion Pharmaceuticals Major Business
9.5.3 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
9.5.4 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Fusion Pharmaceuticals Recent Developments/Updates
9.5.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
9.6 Telix Pharmaceuticals
9.6.1 Telix Pharmaceuticals Details
9.6.2 Telix Pharmaceuticals Major Business
9.6.3 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
9.6.4 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Telix Pharmaceuticals Recent Developments/Updates
9.6.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
9.7 RayzeBio
9.7.1 RayzeBio Details
9.7.2 RayzeBio Major Business
9.7.3 RayzeBio Alpha-emitting Radiopharmaceutical Product and Services
9.7.4 RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 RayzeBio Recent Developments/Updates
9.7.6 RayzeBio Competitive Strengths & Weaknesses
9.8 Orano Med
9.8.1 Orano Med Details
9.8.2 Orano Med Major Business
9.8.3 Orano Med Alpha-emitting Radiopharmaceutical Product and Services
9.8.4 Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Orano Med Recent Developments/Updates
9.8.6 Orano Med Competitive Strengths & Weaknesses
9.9 Actinium Pharmaceuticals
9.9.1 Actinium Pharmaceuticals Details
9.9.2 Actinium Pharmaceuticals Major Business
9.9.3 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
9.9.4 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Actinium Pharmaceuticals Recent Developments/Updates
9.9.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
9.10 Alpha-9 Theranostics
9.10.1 Alpha-9 Theranostics Details
9.10.2 Alpha-9 Theranostics Major Business
9.10.3 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Services
9.10.4 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Alpha-9 Theranostics Recent Developments/Updates
9.10.6 Alpha-9 Theranostics Competitive Strengths & Weaknesses
9.11 AdvanCell
9.11.1 AdvanCell Details
9.11.2 AdvanCell Major Business
9.11.3 AdvanCell Alpha-emitting Radiopharmaceutical Product and Services
9.11.4 AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 AdvanCell Recent Developments/Updates
9.11.6 AdvanCell Competitive Strengths & Weaknesses
9.12 ITM Isotope Technologies Munich
9.12.1 ITM Isotope Technologies Munich Details
9.12.2 ITM Isotope Technologies Munich Major Business
9.12.3 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Services
9.12.4 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 ITM Isotope Technologies Munich Recent Developments/Updates
9.12.6 ITM Isotope Technologies Munich Competitive Strengths & Weaknesses
9.13 Curium
9.13.1 Curium Details
9.13.2 Curium Major Business
9.13.3 Curium Alpha-emitting Radiopharmaceutical Product and Services
9.13.4 Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Curium Recent Developments/Updates
9.13.6 Curium Competitive Strengths & Weaknesses
9.14 China Isotope & Radiation
9.14.1 China Isotope & Radiation Details
9.14.2 China Isotope & Radiation Major Business
9.14.3 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Services
9.14.4 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 China Isotope & Radiation Recent Developments/Updates
9.14.6 China Isotope & Radiation Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Alpha-emitting Radiopharmaceutical Industry Chain
10.2 Alpha-emitting Radiopharmaceutical Upstream Analysis
10.3 Alpha-emitting Radiopharmaceutical Midstream Analysis
10.4 Alpha-emitting Radiopharmaceutical Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Alpha-emitting Radiopharmaceutical Introduction
1.2 World Alpha-emitting Radiopharmaceutical Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Alpha-emitting Radiopharmaceutical Total Market by Region (by Headquarter Location)
1.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.3 China Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.4 Europe Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.5 Japan Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.6 South Korea Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.7 ASEAN Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.3.8 India Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Alpha-emitting Radiopharmaceutical Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.2 World Alpha-emitting Radiopharmaceutical Consumption Value by Region
2.2.1 World Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026)
2.2.2 World Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Region (2027-2032)
2.3 United States Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.4 China Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.5 Europe Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.6 Japan Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.7 South Korea Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.8 ASEAN Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
2.9 India Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032)
3 WORLD ALPHA-EMITTING RADIOPHARMACEUTICAL COMPANIES COMPETITIVE ANALYSIS
3.1 World Alpha-emitting Radiopharmaceutical Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Alpha-emitting Radiopharmaceutical Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Alpha-emitting Radiopharmaceutical in 2025
3.2.3 Global Concentration Ratios (CR8) for Alpha-emitting Radiopharmaceutical in 2025
3.3 Alpha-emitting Radiopharmaceutical Company Evaluation Quadrant
3.4 Alpha-emitting Radiopharmaceutical Market: Overall Company Footprint Analysis
3.4.1 Alpha-emitting Radiopharmaceutical Market: Region Footprint
3.4.2 Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
3.4.3 Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Alpha-emitting Radiopharmaceutical Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Alpha-emitting Radiopharmaceutical Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Alpha-emitting Radiopharmaceutical Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Alpha-emitting Radiopharmaceutical Consumption Value Comparison
4.2.1 United States VS China: Alpha-emitting Radiopharmaceutical Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Alpha-emitting Radiopharmaceutical Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Alpha-emitting Radiopharmaceutical Companies and Market Share, 2021-2026
4.3.1 United States Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026)
4.4 China Based Companies Alpha-emitting Radiopharmaceutical Revenue and Market Share, 2021-2026
4.4.1 China Based Alpha-emitting Radiopharmaceutical Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026)
4.5 Rest of World Based Alpha-emitting Radiopharmaceutical Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Alpha-emitting Radiopharmaceutical Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Actinium-225 Radiopharmaceuticals
5.2.2 Radium-223 Radiopharmaceuticals
5.2.3 Lead-212 Radiopharmaceuticals
5.2.4 Astatine-211 Radiopharmaceuticals
5.2.5 Bismuth-213 Radiopharmaceuticals
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
5.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Type (2027-2032)
5.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY INDICATION
6.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Indication: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Indication
6.2.1 Prostate Cancer Targeted Agents
6.2.2 Neuroendocrine Tumor Agents
6.2.3 Hematologic Malignancy Agents
6.2.4 Solid Tumor Agents
6.2.5 Companion Diagnostic Enabled
6.2.6 Other
6.3 Market Segment by Indication
6.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Indication (2021-2026)
6.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Indication (2027-2032)
6.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication (2027-2032)
7 MARKET ANALYSIS BY SUPPLY FORM
7.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Supply Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Supply Form
7.2.1 Ready-To-Use Injection
7.2.2 Radiolabeling Kit
7.2.3 Isotope Precursor
7.2.4 Other
7.3 Market Segment by Supply Form
7.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Supply Form (2021-2026)
7.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Supply Form (2027-2032)
7.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Alpha-emitting Radiopharmaceutical Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Prostate Cancer
8.2.2 Bone Metastases
8.2.3 Neuroendocrine Tumors
8.2.4 Hematologic Malignancies
8.2.5 Other Solid Tumors
8.2.6 Other
8.3 Market Segment by Application
8.3.1 World Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026)
8.3.2 World Alpha-emitting Radiopharmaceutical Market Size by Application (2027-2032)
8.3.3 World Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Bayer
9.1.1 Bayer Details
9.1.2 Bayer Major Business
9.1.3 Bayer Alpha-emitting Radiopharmaceutical Product and Services
9.1.4 Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Bayer Recent Developments/Updates
9.1.6 Bayer Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Alpha-emitting Radiopharmaceutical Product and Services
9.2.4 Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Eli Lilly
9.3.1 Eli Lilly Details
9.3.2 Eli Lilly Major Business
9.3.3 Eli Lilly Alpha-emitting Radiopharmaceutical Product and Services
9.3.4 Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Eli Lilly Recent Developments/Updates
9.3.6 Eli Lilly Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca Alpha-emitting Radiopharmaceutical Product and Services
9.4.4 AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Fusion Pharmaceuticals
9.5.1 Fusion Pharmaceuticals Details
9.5.2 Fusion Pharmaceuticals Major Business
9.5.3 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
9.5.4 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Fusion Pharmaceuticals Recent Developments/Updates
9.5.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
9.6 Telix Pharmaceuticals
9.6.1 Telix Pharmaceuticals Details
9.6.2 Telix Pharmaceuticals Major Business
9.6.3 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
9.6.4 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Telix Pharmaceuticals Recent Developments/Updates
9.6.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
9.7 RayzeBio
9.7.1 RayzeBio Details
9.7.2 RayzeBio Major Business
9.7.3 RayzeBio Alpha-emitting Radiopharmaceutical Product and Services
9.7.4 RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 RayzeBio Recent Developments/Updates
9.7.6 RayzeBio Competitive Strengths & Weaknesses
9.8 Orano Med
9.8.1 Orano Med Details
9.8.2 Orano Med Major Business
9.8.3 Orano Med Alpha-emitting Radiopharmaceutical Product and Services
9.8.4 Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Orano Med Recent Developments/Updates
9.8.6 Orano Med Competitive Strengths & Weaknesses
9.9 Actinium Pharmaceuticals
9.9.1 Actinium Pharmaceuticals Details
9.9.2 Actinium Pharmaceuticals Major Business
9.9.3 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
9.9.4 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Actinium Pharmaceuticals Recent Developments/Updates
9.9.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
9.10 Alpha-9 Theranostics
9.10.1 Alpha-9 Theranostics Details
9.10.2 Alpha-9 Theranostics Major Business
9.10.3 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Services
9.10.4 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Alpha-9 Theranostics Recent Developments/Updates
9.10.6 Alpha-9 Theranostics Competitive Strengths & Weaknesses
9.11 AdvanCell
9.11.1 AdvanCell Details
9.11.2 AdvanCell Major Business
9.11.3 AdvanCell Alpha-emitting Radiopharmaceutical Product and Services
9.11.4 AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 AdvanCell Recent Developments/Updates
9.11.6 AdvanCell Competitive Strengths & Weaknesses
9.12 ITM Isotope Technologies Munich
9.12.1 ITM Isotope Technologies Munich Details
9.12.2 ITM Isotope Technologies Munich Major Business
9.12.3 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Services
9.12.4 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 ITM Isotope Technologies Munich Recent Developments/Updates
9.12.6 ITM Isotope Technologies Munich Competitive Strengths & Weaknesses
9.13 Curium
9.13.1 Curium Details
9.13.2 Curium Major Business
9.13.3 Curium Alpha-emitting Radiopharmaceutical Product and Services
9.13.4 Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Curium Recent Developments/Updates
9.13.6 Curium Competitive Strengths & Weaknesses
9.14 China Isotope & Radiation
9.14.1 China Isotope & Radiation Details
9.14.2 China Isotope & Radiation Major Business
9.14.3 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Services
9.14.4 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 China Isotope & Radiation Recent Developments/Updates
9.14.6 China Isotope & Radiation Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Alpha-emitting Radiopharmaceutical Industry Chain
10.2 Alpha-emitting Radiopharmaceutical Upstream Analysis
10.3 Alpha-emitting Radiopharmaceutical Midstream Analysis
10.4 Alpha-emitting Radiopharmaceutical Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Alpha-emitting Radiopharmaceutical Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Alpha-emitting Radiopharmaceutical Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Alpha-emitting Radiopharmaceutical Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Alpha-emitting Radiopharmaceutical Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Alpha-emitting Radiopharmaceutical Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Alpha-emitting Radiopharmaceutical Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Alpha-emitting Radiopharmaceutical Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Alpha-emitting Radiopharmaceutical Players in 2025
Table 12. World Alpha-emitting Radiopharmaceutical Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Alpha-emitting Radiopharmaceutical Company Evaluation Quadrant
Table 14. Head Office of Key Alpha-emitting Radiopharmaceutical Players
Table 15. Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
Table 16. Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
Table 17. Alpha-emitting Radiopharmaceutical Mergers & Acquisitions Activity
Table 18. United States VS China Alpha-emitting Radiopharmaceutical Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Alpha-emitting Radiopharmaceutical Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (States, Country)
Table 21. United States Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Alpha-emitting Radiopharmaceutical Revenue Market Share (2021-2026)
Table 23. China Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (Province, Country)
Table 24. China Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Alpha-emitting Radiopharmaceutical Revenue Market Share (2021-2026)
Table 26. Rest of World Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Alpha-emitting Radiopharmaceutical Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Alpha-emitting Radiopharmaceutical Revenue Market Share (2021-2026)
Table 29. World Alpha-emitting Radiopharmaceutical Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Alpha-emitting Radiopharmaceutical Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Alpha-emitting Radiopharmaceutical Market Size by Type (2027-2032) & (USD Million)
Table 32. World Alpha-emitting Radiopharmaceutical Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Table 33. World Alpha-emitting Radiopharmaceutical Market Size Value by Indication (2021-2026) & (USD Million)
Table 34. World Alpha-emitting Radiopharmaceutical Market Size by Indication (2027-2032) & (USD Million)
Table 35. World Alpha-emitting Radiopharmaceutical Market Size by Supply Form, (USD Million), 2021 & 2025 & 2032
Table 36. World Alpha-emitting Radiopharmaceutical Market Size Value by Supply Form (2021-2026) & (USD Million)
Table 37. World Alpha-emitting Radiopharmaceutical Market Size by Supply Form (2027-2032) & (USD Million)
Table 38. World Alpha-emitting Radiopharmaceutical Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026) & (USD Million)
Table 40. World Alpha-emitting Radiopharmaceutical Market Size by Application (2027-2032) & (USD Million)
Table 41. Bayer Basic Information, Manufacturing Base and Competitors
Table 42. Bayer Major Business
Table 43. Bayer Alpha-emitting Radiopharmaceutical Product and Services
Table 44. Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Bayer Recent Developments/Updates
Table 46. Bayer Competitive Strengths & Weaknesses
Table 47. Novartis Basic Information, Manufacturing Base and Competitors
Table 48. Novartis Major Business
Table 49. Novartis Alpha-emitting Radiopharmaceutical Product and Services
Table 50. Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Novartis Recent Developments/Updates
Table 52. Novartis Competitive Strengths & Weaknesses
Table 53. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 54. Eli Lilly Major Business
Table 55. Eli Lilly Alpha-emitting Radiopharmaceutical Product and Services
Table 56. Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Eli Lilly Recent Developments/Updates
Table 58. Eli Lilly Competitive Strengths & Weaknesses
Table 59. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca Major Business
Table 61. AstraZeneca Alpha-emitting Radiopharmaceutical Product and Services
Table 62. AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca Recent Developments/Updates
Table 64. AstraZeneca Competitive Strengths & Weaknesses
Table 65. Fusion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 66. Fusion Pharmaceuticals Major Business
Table 67. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
Table 68. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Fusion Pharmaceuticals Recent Developments/Updates
Table 70. Fusion Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Telix Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 72. Telix Pharmaceuticals Major Business
Table 73. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
Table 74. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Telix Pharmaceuticals Recent Developments/Updates
Table 76. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. RayzeBio Basic Information, Manufacturing Base and Competitors
Table 78. RayzeBio Major Business
Table 79. RayzeBio Alpha-emitting Radiopharmaceutical Product and Services
Table 80. RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. RayzeBio Recent Developments/Updates
Table 82. RayzeBio Competitive Strengths & Weaknesses
Table 83. Orano Med Basic Information, Manufacturing Base and Competitors
Table 84. Orano Med Major Business
Table 85. Orano Med Alpha-emitting Radiopharmaceutical Product and Services
Table 86. Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Orano Med Recent Developments/Updates
Table 88. Orano Med Competitive Strengths & Weaknesses
Table 89. Actinium Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 90. Actinium Pharmaceuticals Major Business
Table 91. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
Table 92. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Actinium Pharmaceuticals Recent Developments/Updates
Table 94. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 95. Alpha-9 Theranostics Basic Information, Manufacturing Base and Competitors
Table 96. Alpha-9 Theranostics Major Business
Table 97. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Services
Table 98. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Alpha-9 Theranostics Recent Developments/Updates
Table 100. Alpha-9 Theranostics Competitive Strengths & Weaknesses
Table 101. AdvanCell Basic Information, Manufacturing Base and Competitors
Table 102. AdvanCell Major Business
Table 103. AdvanCell Alpha-emitting Radiopharmaceutical Product and Services
Table 104. AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. AdvanCell Recent Developments/Updates
Table 106. AdvanCell Competitive Strengths & Weaknesses
Table 107. ITM Isotope Technologies Munich Basic Information, Manufacturing Base and Competitors
Table 108. ITM Isotope Technologies Munich Major Business
Table 109. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Services
Table 110. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. ITM Isotope Technologies Munich Recent Developments/Updates
Table 112. ITM Isotope Technologies Munich Competitive Strengths & Weaknesses
Table 113. Curium Basic Information, Manufacturing Base and Competitors
Table 114. Curium Major Business
Table 115. Curium Alpha-emitting Radiopharmaceutical Product and Services
Table 116. Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Curium Recent Developments/Updates
Table 118. Curium Competitive Strengths & Weaknesses
Table 119. China Isotope & Radiation Basic Information, Manufacturing Base and Competitors
Table 120. China Isotope & Radiation Major Business
Table 121. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Services
Table 122. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. China Isotope & Radiation Recent Developments/Updates
Table 124. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 125. Global Key Players of Alpha-emitting Radiopharmaceutical Upstream (Raw Materials)
Table 126. Global Alpha-emitting Radiopharmaceutical Typical Customers
Table 1. World Alpha-emitting Radiopharmaceutical Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Alpha-emitting Radiopharmaceutical Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Alpha-emitting Radiopharmaceutical Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Alpha-emitting Radiopharmaceutical Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Alpha-emitting Radiopharmaceutical Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Alpha-emitting Radiopharmaceutical Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Alpha-emitting Radiopharmaceutical Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Alpha-emitting Radiopharmaceutical Players in 2025
Table 12. World Alpha-emitting Radiopharmaceutical Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Alpha-emitting Radiopharmaceutical Company Evaluation Quadrant
Table 14. Head Office of Key Alpha-emitting Radiopharmaceutical Players
Table 15. Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
Table 16. Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
Table 17. Alpha-emitting Radiopharmaceutical Mergers & Acquisitions Activity
Table 18. United States VS China Alpha-emitting Radiopharmaceutical Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Alpha-emitting Radiopharmaceutical Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (States, Country)
Table 21. United States Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Alpha-emitting Radiopharmaceutical Revenue Market Share (2021-2026)
Table 23. China Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (Province, Country)
Table 24. China Based Companies Alpha-emitting Radiopharmaceutical Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Alpha-emitting Radiopharmaceutical Revenue Market Share (2021-2026)
Table 26. Rest of World Based Alpha-emitting Radiopharmaceutical Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Alpha-emitting Radiopharmaceutical Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Alpha-emitting Radiopharmaceutical Revenue Market Share (2021-2026)
Table 29. World Alpha-emitting Radiopharmaceutical Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Alpha-emitting Radiopharmaceutical Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Alpha-emitting Radiopharmaceutical Market Size by Type (2027-2032) & (USD Million)
Table 32. World Alpha-emitting Radiopharmaceutical Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Table 33. World Alpha-emitting Radiopharmaceutical Market Size Value by Indication (2021-2026) & (USD Million)
Table 34. World Alpha-emitting Radiopharmaceutical Market Size by Indication (2027-2032) & (USD Million)
Table 35. World Alpha-emitting Radiopharmaceutical Market Size by Supply Form, (USD Million), 2021 & 2025 & 2032
Table 36. World Alpha-emitting Radiopharmaceutical Market Size Value by Supply Form (2021-2026) & (USD Million)
Table 37. World Alpha-emitting Radiopharmaceutical Market Size by Supply Form (2027-2032) & (USD Million)
Table 38. World Alpha-emitting Radiopharmaceutical Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026) & (USD Million)
Table 40. World Alpha-emitting Radiopharmaceutical Market Size by Application (2027-2032) & (USD Million)
Table 41. Bayer Basic Information, Manufacturing Base and Competitors
Table 42. Bayer Major Business
Table 43. Bayer Alpha-emitting Radiopharmaceutical Product and Services
Table 44. Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Bayer Recent Developments/Updates
Table 46. Bayer Competitive Strengths & Weaknesses
Table 47. Novartis Basic Information, Manufacturing Base and Competitors
Table 48. Novartis Major Business
Table 49. Novartis Alpha-emitting Radiopharmaceutical Product and Services
Table 50. Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Novartis Recent Developments/Updates
Table 52. Novartis Competitive Strengths & Weaknesses
Table 53. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 54. Eli Lilly Major Business
Table 55. Eli Lilly Alpha-emitting Radiopharmaceutical Product and Services
Table 56. Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Eli Lilly Recent Developments/Updates
Table 58. Eli Lilly Competitive Strengths & Weaknesses
Table 59. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca Major Business
Table 61. AstraZeneca Alpha-emitting Radiopharmaceutical Product and Services
Table 62. AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca Recent Developments/Updates
Table 64. AstraZeneca Competitive Strengths & Weaknesses
Table 65. Fusion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 66. Fusion Pharmaceuticals Major Business
Table 67. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
Table 68. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Fusion Pharmaceuticals Recent Developments/Updates
Table 70. Fusion Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Telix Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 72. Telix Pharmaceuticals Major Business
Table 73. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
Table 74. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Telix Pharmaceuticals Recent Developments/Updates
Table 76. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. RayzeBio Basic Information, Manufacturing Base and Competitors
Table 78. RayzeBio Major Business
Table 79. RayzeBio Alpha-emitting Radiopharmaceutical Product and Services
Table 80. RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. RayzeBio Recent Developments/Updates
Table 82. RayzeBio Competitive Strengths & Weaknesses
Table 83. Orano Med Basic Information, Manufacturing Base and Competitors
Table 84. Orano Med Major Business
Table 85. Orano Med Alpha-emitting Radiopharmaceutical Product and Services
Table 86. Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Orano Med Recent Developments/Updates
Table 88. Orano Med Competitive Strengths & Weaknesses
Table 89. Actinium Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 90. Actinium Pharmaceuticals Major Business
Table 91. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Services
Table 92. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Actinium Pharmaceuticals Recent Developments/Updates
Table 94. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 95. Alpha-9 Theranostics Basic Information, Manufacturing Base and Competitors
Table 96. Alpha-9 Theranostics Major Business
Table 97. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Services
Table 98. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Alpha-9 Theranostics Recent Developments/Updates
Table 100. Alpha-9 Theranostics Competitive Strengths & Weaknesses
Table 101. AdvanCell Basic Information, Manufacturing Base and Competitors
Table 102. AdvanCell Major Business
Table 103. AdvanCell Alpha-emitting Radiopharmaceutical Product and Services
Table 104. AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. AdvanCell Recent Developments/Updates
Table 106. AdvanCell Competitive Strengths & Weaknesses
Table 107. ITM Isotope Technologies Munich Basic Information, Manufacturing Base and Competitors
Table 108. ITM Isotope Technologies Munich Major Business
Table 109. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Services
Table 110. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. ITM Isotope Technologies Munich Recent Developments/Updates
Table 112. ITM Isotope Technologies Munich Competitive Strengths & Weaknesses
Table 113. Curium Basic Information, Manufacturing Base and Competitors
Table 114. Curium Major Business
Table 115. Curium Alpha-emitting Radiopharmaceutical Product and Services
Table 116. Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Curium Recent Developments/Updates
Table 118. Curium Competitive Strengths & Weaknesses
Table 119. China Isotope & Radiation Basic Information, Manufacturing Base and Competitors
Table 120. China Isotope & Radiation Major Business
Table 121. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Services
Table 122. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. China Isotope & Radiation Recent Developments/Updates
Table 124. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 125. Global Key Players of Alpha-emitting Radiopharmaceutical Upstream (Raw Materials)
Table 126. Global Alpha-emitting Radiopharmaceutical Typical Customers
LIST OF FIGURES
Figure 1. Alpha-emitting Radiopharmaceutical Picture
Figure 2. World Alpha-emitting Radiopharmaceutical Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Alpha-emitting Radiopharmaceutical Total Revenue (2021-2032) & (USD Million)
Figure 4. World Alpha-emitting Radiopharmaceutical Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Alpha-emitting Radiopharmaceutical Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 13. Alpha-emitting Radiopharmaceutical Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 16. World Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 18. China Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 23. India Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Alpha-emitting Radiopharmaceutical by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Alpha-emitting Radiopharmaceutical Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Alpha-emitting Radiopharmaceutical Markets in 2025
Figure 27. United States VS China: Alpha-emitting Radiopharmaceutical Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Alpha-emitting Radiopharmaceutical Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Alpha-emitting Radiopharmaceutical Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Type in 2025
Figure 31. Actinium-225 Radiopharmaceuticals
Figure 32. Radium-223 Radiopharmaceuticals
Figure 33. Lead-212 Radiopharmaceuticals
Figure 34. Astatine-211 Radiopharmaceuticals
Figure 35. Bismuth-213 Radiopharmaceuticals
Figure 36. Other
Figure 37. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2032)
Figure 38. World Alpha-emitting Radiopharmaceutical Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Figure 39. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication in 2025
Figure 40. Prostate Cancer Targeted Agents
Figure 41. Neuroendocrine Tumor Agents
Figure 42. Hematologic Malignancy Agents
Figure 43. Solid Tumor Agents
Figure 44. Companion Diagnostic Enabled
Figure 45. Other
Figure 46. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication (2021-2032)
Figure 47. World Alpha-emitting Radiopharmaceutical Market Size by Supply Form, (USD Million), 2021 & 2025 & 2032
Figure 48. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form in 2025
Figure 49. Ready-To-Use Injection
Figure 50. Radiolabeling Kit
Figure 51. Isotope Precursor
Figure 52. Other
Figure 53. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form (2021-2032)
Figure 54. World Alpha-emitting Radiopharmaceutical Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Application in 2025
Figure 56. Prostate Cancer
Figure 57. Bone Metastases
Figure 58. Neuroendocrine Tumors
Figure 59. Hematologic Malignancies
Figure 60. Other Solid Tumors
Figure 61. Other
Figure 62. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2032)
Figure 63. Alpha-emitting Radiopharmaceutical Industrial Chain
Figure 64. Methodology
Figure 65. Research Process and Data Source
Figure 1. Alpha-emitting Radiopharmaceutical Picture
Figure 2. World Alpha-emitting Radiopharmaceutical Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Alpha-emitting Radiopharmaceutical Total Revenue (2021-2032) & (USD Million)
Figure 4. World Alpha-emitting Radiopharmaceutical Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Alpha-emitting Radiopharmaceutical Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Alpha-emitting Radiopharmaceutical Revenue (2021-2032) & (USD Million)
Figure 13. Alpha-emitting Radiopharmaceutical Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 16. World Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 18. China Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 23. India Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Alpha-emitting Radiopharmaceutical by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Alpha-emitting Radiopharmaceutical Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Alpha-emitting Radiopharmaceutical Markets in 2025
Figure 27. United States VS China: Alpha-emitting Radiopharmaceutical Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Alpha-emitting Radiopharmaceutical Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Alpha-emitting Radiopharmaceutical Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Type in 2025
Figure 31. Actinium-225 Radiopharmaceuticals
Figure 32. Radium-223 Radiopharmaceuticals
Figure 33. Lead-212 Radiopharmaceuticals
Figure 34. Astatine-211 Radiopharmaceuticals
Figure 35. Bismuth-213 Radiopharmaceuticals
Figure 36. Other
Figure 37. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2032)
Figure 38. World Alpha-emitting Radiopharmaceutical Market Size by Indication, (USD Million), 2021 & 2025 & 2032
Figure 39. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication in 2025
Figure 40. Prostate Cancer Targeted Agents
Figure 41. Neuroendocrine Tumor Agents
Figure 42. Hematologic Malignancy Agents
Figure 43. Solid Tumor Agents
Figure 44. Companion Diagnostic Enabled
Figure 45. Other
Figure 46. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication (2021-2032)
Figure 47. World Alpha-emitting Radiopharmaceutical Market Size by Supply Form, (USD Million), 2021 & 2025 & 2032
Figure 48. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form in 2025
Figure 49. Ready-To-Use Injection
Figure 50. Radiolabeling Kit
Figure 51. Isotope Precursor
Figure 52. Other
Figure 53. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form (2021-2032)
Figure 54. World Alpha-emitting Radiopharmaceutical Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Application in 2025
Figure 56. Prostate Cancer
Figure 57. Bone Metastases
Figure 58. Neuroendocrine Tumors
Figure 59. Hematologic Malignancies
Figure 60. Other Solid Tumors
Figure 61. Other
Figure 62. World Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2032)
Figure 63. Alpha-emitting Radiopharmaceutical Industrial Chain
Figure 64. Methodology
Figure 65. Research Process and Data Source
